Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 674
- Registration Number
- NCT01296555
- Locations
- 🇺🇸
Univ of Chicago, Chicago, Illinois, United States
🇺🇸Mary Crowley Cancer Rsch Ctr, Dallas, Texas, United States
🇺🇸Baylor Sammons Cancer Center, Dallas, Texas, United States
BAY73-4506 Probe Substrate Study
- Conditions
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 41
- Registration Number
- NCT01287598
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada
A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT01275170
Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine
- Conditions
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- Hospital Sao Domingos
- Target Recruit Count
- 146
- Registration Number
- NCT01256866
- Locations
- 🇧🇷
Hospital Sao Domingos, Sao Luis, Maranhao, Brazil
The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT01221727
Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT01215214
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT01209832
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France
Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement
- Conditions
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01188551
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
A Study to Assess Drug Interaction of ASP015K and Midazolam
- Conditions
- Interventions
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01182077
Resveratrol and Midazolam Metabolism
- Conditions
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 6
- Registration Number
- NCT01173640
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.